UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

Leukemia, 2010-06, Vol.24 (6), p.1121-1127

2010

Volltextzugriff (PDF)

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

Leukemia, 2009-09, Vol.23 (9), p.1545-1556

2009

Volltextzugriff (PDF)

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

Leukemia, 2013-04, Vol.27 (4), p.941-946

2013

Volltextzugriff (PDF)

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

Leukemia, 2013-08, Vol.27 (8), p.1738-1744

2013

Volltextzugriff (PDF)

International uniform response criteria for multiple myeloma

Leukemia, 2006-09, Vol.20 (9), p.1467-1473

2006

Volltextzugriff (PDF)

N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression

Leukemia, 2020-10, Vol.34 (10), p.2749-2753

2020

Volltextzugriff (PDF)

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Leukemia, 2016-11, Vol.30 (11), p.2208-2213

2016

Volltextzugriff (PDF)

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

Leukemia, 2011-06, Vol.25 (6), p.906-908

2011

Volltextzugriff (PDF)

Genetic aberrations and survival in plasma cell leukemia

Leukemia, 2008-05, Vol.22 (5), p.1044-1052

2008

Volltextzugriff (PDF)

Treatment of newly diagnosed myeloma

Leukemia, 2009-03, Vol.23 (3), p.449-456

2009

Volltextzugriff (PDF)

Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma

Leukemia, 2014-10, Vol.28 (10), p.2060-2065

2014

Volltextzugriff (PDF)

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma

Leukemia, 2013-03, Vol.27 (3), p.680-685

2013

Volltextzugriff (PDF)

Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites

Leukemia, 2012-04, Vol.26 (4), p.609-614

2012

Volltextzugriff (PDF)

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Leukemia, 2010-11, Vol.24 (11), p.1934-1939

2010

Volltextzugriff (PDF)

Clinically relevant end points and new drug approvals for myeloma

Leukemia, 2008-02, Vol.22 (2), p.231-239

2008

Volltextzugriff (PDF)

Management of treatment-emergent peripheral neuropathy in multiple myeloma

Leukemia, 2012-04, Vol.26 (4), p.595-608

2012

Volltextzugriff (PDF)

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Leukemia, 2024-08, Vol.38 (8), p.1866-1866

2024

Volltextzugriff (PDF)

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Leukemia, 2021-12, Vol.35 (12), p.3604-3607

2021

Volltextzugriff (PDF)

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

Leukemia, 2013-03, Vol.27 (3), p.711-717

2013

Volltextzugriff (PDF)

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

Leukemia, 2007-09, Vol.21 (9), p.2035-2042

2007

Volltextzugriff (PDF)

Sorafenib, a dual Raf kinase vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

Oncogene, 2010-02, Vol.29 (8), p.1190-1202

2010

Volltextzugriff (PDF)

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Leukemia, 2009-02, Vol.23 (2), p.215-224

2009

Volltextzugriff (PDF)

Clarification of the definition of complete response in multiple myeloma

Leukemia, 2015-12, Vol.29 (12), p.2416-2417

2015

Volltextzugriff (PDF)

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

Leukemia, 2016-03, Vol.30 (3), p.633-639

2016

Volltextzugriff (PDF)

Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system

Leukemia, 2008-10, Vol.22 (10), p.1933-1937

2008

Volltextzugriff (PDF)

1 – 25 von 2.788

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.934)
Mit Volltextzugriff
(2.301)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.450)
Life Sciences & Biomedicine
(868)
Humans
(589)
Technology
(466)
Male
(336)
Female
(335)
Middle Aged
(272)
Biological And Medical Sciences
(261)
Hematology
(253)
Oncology
(251)
Aged
(247)
Physical Sciences
(241)
Adult
(225)
Medical Sciences
(220)
Materials Science
(174)
Computer Science
(165)
Engineering
(164)
Multiple Myeloma
(154)
Materials Science, Multidisciplinary
(139)
Prognosis
(119)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Free E-Journals
(1.102)
Ingenta
(799)
MEDLINE
(682)
Journals@Ovid Ovid Full Text
(610)
Ebook Central Perpetual and DDA
(411)
eBooks on EBSCOhost
(408)
Elsevier ScienceDirect Journals Complete
(342)
IngentaConnect Journals
(330)
Publisher or Other Site
(313)
Nature
(205)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(194)
IEEE Electronic Library (IEL)
(188)
Wiley Online Library
(177)
Springer Online Journals
(170)
Nexis Uni
(161)
Wiley Online Library Full Collection 2018
(131)
SpringerLink Series
(112)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(106)
Taylor & Francis Online
(55)
Taylor & Francis Journals
(53)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

International uniform response criteria for multiple myeloma

N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

Genetic aberrations and survival in plasma cell leukemia

Treatment of newly diagnosed myeloma

Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma

Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Clinically relevant end points and new drug approvals for myeloma

Management of treatment-emergent peripheral neuropathy in multiple myeloma

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

Sorafenib, a dual Raf kinase vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Clarification of the definition of complete response in multiple myeloma

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system

Suchergebnisse filtern